Hepatitis

After about two years of treatment with the experimental therapies tobevibart and elebsiran, nearly nine out of 10 evaluable…

Bepirovirsen added to standard-of-care medications led to higher functional cure rates for people with chronic hepatitis B than standard treatments alone, according to top-line…

Health Canada has expanded its approval of Abbvie’s oral therapy Maviret (glecaprevir/pibrentasvir), making it the first eight-week, pan-genotypic treatment available for both acute and…

Throughout 2025, the team at Liver Disease News has reported on the latest research and advances in care related to various rare and non-rare liver…

Researchers in the U.S. have developed a rapid point-of-care test that detects active hepatitis C infection by identifying HCV RNA, with results available in…

Major medical associations and state health departments are moving to maintain the standard of universal hepatitis B vaccination at birth, diverging from a recent…

People with hepatitis C who show higher values of liver scarring markers before starting antiviral therapy are significantly more likely to later develop…

New modeling data predict that bemnifosbuvir and ruzasvir, an experimental combination treatment being developed by Atea Pharmaceuticals for chronic hepatitis C, may…

PBGENE-HBV, Precision BioSciences’ experimental gene-editing therapy for chronic hepatitis B, showed antiviral activity across three doses, with the highest dose approaching the benchmark…

Enrollment is now complete for Vir Biotechnology’s global ECLIPSE 1 trial, which is testing the combination treatment of tobevibart and elebsiran in people with chronic…